Intensive Uric Acid Lowering with Verinurad and Febuxostat in Patients with Albuminuria

Trial Identifier: D5495C00007
Sponsor: AstraZeneca
NCTID:: NCT03118739
Start Date: May 2017
Primary Completion Date: August 2018
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
Spanish Translation

Trial Locations

Country Location
United States of America, CA Canyon Country, CA, United States of America, 91351
United States of America, CA Chula Vista, CA, United States of America, 91911
United States of America, CA Corona, CA, United States of America, 92882
United States of America, CA Escondido, CA, United States of America, 92025
United States of America, CA Lakewood, CA, United States of America, 90805
United States of America, CA Lincoln, CA, United States of America, 95648
United States of America, CA Los Angeles, CA, United States of America, 90036
United States of America, CA Los Angeles, CA, United States of America, 90022
United States of America, CA Los Angeles, CA, United States of America, 90017
United States of America, CA North Hollywood, CA, United States of America, 91606
United States of America, CA Oceanside, CA, United States of America, 92056-4510
United States of America, CA Orange, CA, United States of America, 92868
United States of America, CA Sacramento, CA, United States of America, 95821
United States of America, CA Sacramento, CA, United States of America, 95825
United States of America, TX Houston, TX, United States of America, 77070
United States of America, TX Houston, TX, United States of America, 77058
United States of America, TX Pearland, TX, United States of America, 77584
United States of America, TX Sugar Land, TX, United States of America, 77478
United States of America, TX Webster, TX, United States of America, 77598